NovoCure (NVCR) said Tuesday that the Optune Lua medical device has received a CE Mark to treat adults with metastatic non-small cell lung cancer who have progressed on or after a platinum-based treatment.
The approval covers the use of the medical device simultaneously with immune checkpoint inhibitors or docetaxel, the company said.
The portable device produces alternating electric fields, called Tumor Treating Fields, which are delivered via wearable arrays, NovoCure said.
NovoCure said it has started the local registration requirements for the device in Germany and is getting ready for launch in the coming weeks.
Optune Lua was also cleared by the US Food and Drug Administration in October, the company said.
NovoCure shares were 4.1% higher in recent trading.
Price: 16.22, Change: +0.64, Percent Change: +4.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.